Health ❯ Healthcare ❯ Clinical Research

Drug Development

Clinical Trials Regulatory Approval Eli Lilly Phase 2 Trials Lecanemab Phase 3 Trials Alzheimer's Treatments Immunotherapy Trials Therapeutic Evaluation Oral Medications Biologic Drugs Antiviral Candidates Gilead Sciences Phase 1 Trials Orforglipron Cardiovascular Disease Innovative Therapies Hepatitis C Virus Antiviral Research Therapeutic Innovations Antimicrobial Resistance Strategies Efficacy Studies Pediatric Medicine LENZ Therapeutics Antisense Oligonucleotides Phase I/II Trials Regulatory Affairs Teplizumab Trials Tirzepatide Efficacy Therapeutics GSK Innovations Antibody-Drug Conjugates (ADCs) Medpace Holdings, Inc. Alzheimer's Disease Therapies Comparative Effectiveness

Design Therapeutics Reports Early DT-216P2 Data in Friedreich’s Ataxia

The company signaled a potential registrational path with an update planned for the fourth quarter.

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

Vulcan Value Partners' Q4 Letter Reports Gains, Deep Discounts and Portfolio Changes

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

EMA Committee Recommends EU Approval for First Oral Postpartum Depression Treatment

Antibiotic Energy Drain Found to Accelerate Bacterial Resistance